S
Steven M. Swanson
Researcher at University of Wisconsin-Madison
Publications - 121
Citations - 4622
Steven M. Swanson is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Cancer & Apoptosis. The author has an hindex of 37, co-authored 117 publications receiving 4189 citations. Previous affiliations of Steven M. Swanson include University of Illinois at Chicago.
Papers
More filters
Journal ArticleDOI
Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris.
Bang Yeon Hwang,Bao Ning Su,Heebyung Chai,Qiuwen Mi,Leonardus B.S. Kardono,Johar J. Afriastini,Soedarsono Riswan,Bernard D. Santarsiero,Andrew D. Mesecar,Robert A. Wild,Craig R. Fairchild,Gregory D. Vite,William C. Rose,Norman R. Farnsworth,Geoffrey A. Cordell,John M. Pezzuto,Steven M. Swanson,A. Douglas Kinghorn +17 more
TL;DR: Two cytotoxic rocaglate derivatives possessing an unusual dioxanyloxy unit, silvestrol and episilvestrol, were isolated from the fruits and twigs of Aglaia silvestris by bioassay-guided fractionation monitored with a human oral epidermoid carcinoma (KB) cell line.
Journal ArticleDOI
Novel Strategies for the Discovery of Plant-Derived Anticancer Agents
A. D. Kinghorn,Norman R. Farnsworth,Djaja D. Soejarto,Geoffrey A. Cordell,Steven M. Swanson,John M. Pezzuto,Mansukh C. Wani,Monroe E. Wall,Nicholas H. Oberlies,David J. Kroll,Robert Kramer,William C. Rose,Gregory D. Vite,Craig Fairchild,Russell Peterson,Robert A. Wild +15 more
TL;DR: Work has continued on the investigation of plants, collected mainly from tropical rainforests, as potential sources of new cancer chemotherapeutic agents, and a number of bioactive compounds of interest to the project are described.
Journal Article
Discovery of natural product anticancer agents from biodiverse organisms.
TL;DR: In the present short review, selected novel compounds that have been obtained from organisms of diverse biological origin, or their derivatives, are discussed in terms of their potential use as cancer chemotherapeutic agents.
Journal ArticleDOI
Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model
Veda Diwadkar-Navsariwala,Gail S. Prins,Steven M. Swanson,Lynn Birch,Vera Ray,Samad Hedayat,Daniel L. Lantvit,Alan M. Diamond +7 more
TL;DR: A unique mouse model was developed by breeding two transgenic animals that exhibited accelerated development of lesions associated with prostate cancer progression, implicating selenoproteins in cancer risk and development and raising the possibility that selenium prevents cancer by modulating the levels of these seleniproteins.
Journal ArticleDOI
Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy.
TL;DR: Based on the published data thus far, cyclopenta[b]benzofurans offer excellent potential as therapeutic agent candidates in cancer chemotherapy, even if much work still remains to be done for their further development.